Building on its platform technology portfolio, Roche has entered into a technology licensing agreement with Amunix Pharmaceuticals for its half-life extension platform, XTEN®, to discover and develop novel therapeutics in non-oncology indications. Details on specific therapy areas and targets have not been publicly disclosed. The deal builds on a previous agreement between the two companies signed in 2013.